Bruening W - Search Results

1

Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary.

Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK. Bruening W, et al. Cancer. 2000 May 1;88(9):2154-63. Cancer. 2000. PMID: 10813729

2

Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways.

Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK. Pan ZZ, et al. Among authors: bruening w. J Biol Chem. 2002 Sep 20;277(38):35050-60. doi: 10.1074/jbc.M201650200. Epub 2002 Jul 16. J Biol Chem. 2002. PMID: 12121974 Free article.

3

Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells.

Bruening W, Prowse AH, Schultz DC, Holgado-Madruga M, Wong A, Godwin AK. Bruening W, et al. Cancer Res. 1999 Oct 1;59(19):4973-83. Cancer Res. 1999. PMID: 10519411

4

Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility.

Pan ZZ, Bruening W, Godwin AK. Pan ZZ, et al. Among authors: bruening w. Int J Oncol. 2006 Nov;29(5):1201-5. Int J Oncol. 2006. PMID: 17016652

5

Activation of stress-activated protein kinases correlates with neurite outgrowth induced by protease inhibition in PC12 cells.

Giasson BI, Bruening W, Durham HD, Mushynski WE. Giasson BI, et al. Among authors: bruening w. J Neurochem. 1999 Mar;72(3):1081-7. doi: 10.1046/j.1471-4159.1999.0721081.x. J Neurochem. 1999. PMID: 10037479 Free article.

6

Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter.

Bruening W, Giasson B, Mushynski W, Durham HD. Bruening W, et al. Nucleic Acids Res. 1998 Jan 15;26(2):486-9. doi: 10.1093/nar/26.2.486. Nucleic Acids Res. 1998. PMID: 9421504 Free PMC article.

7

Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis.

Bruening W, Roy J, Giasson B, Figlewicz DA, Mushynski WE, Durham HD. Bruening W, et al. J Neurochem. 1999 Feb;72(2):693-9. doi: 10.1046/j.1471-4159.1999.0720693.x. J Neurochem. 1999. PMID: 9930742 Free article.

8

Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors.

Bruening W, Gros P, Sato T, Stanimir J, Nakamura Y, Housman D, Pelletier J. Bruening W, et al. Cancer Invest. 1993;11(4):393-9. doi: 10.3109/07357909309018871. Cancer Invest. 1993. PMID: 8324644

9

A non-AUG translational initiation event generates novel WT1 isoforms.

Bruening W, Pelletier J. Bruening W, et al. J Biol Chem. 1996 Apr 12;271(15):8646-54. doi: 10.1074/jbc.271.15.8646. J Biol Chem. 1996. PMID: 8621495 Free article.

10

Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development.

Bruening W, Bardeesy N, Silverman BL, Cohn RA, Machin GA, Aronson AJ, Housman D, Pelletier J. Bruening W, et al. Nat Genet. 1992 May;1(2):144-8. doi: 10.1038/ng0592-144. Nat Genet. 1992. PMID: 1302008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters